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ABSTRACT 
Arterial remodeling is a major pathophysiological mechanism underlying clinical cardiovascular 
disorders such as hypertension, atherosclerosis and restenosis. We examined heparan sulfate 
proteoglycan homeostasis as a mechanism of regulation of arterial vascular remodeling in 
response to altered mechanical environments such as hypertension and injury. We first studied 
the effect of in-vitro mechanical strain on the ability of endothelial cells to inhibit vascular 
smooth muscle cell proliferation. Under these conditions we found mechanical strain increased 
endothelial inhibition of smooth muscle cell proliferation through increased production of 
heparan sulfate proteoglycans. Using inhibitors to p38 MAPK and ERK, we showed that 
activation of both of these pathways was essential for load-induced heparan sulfate production, 
TGF-31 activation, smad-2 activation and increased FGF-2 uptake. Further, we exposed cells to 
strain in the presence of a neutralizing antibody to TGF-31 and demonstrated that autocrine TGF- 
PI signaling was essential for load-induced HSPG production and sustained p38 MAPK and ERK 
activation. We also examined the endothelium of spontaneously hypertensive rats using 
immunohistochemical staining for heparan sulfate proteoglycan core proteins, TGF-p1 and 
phosphorylated signaling intermediates and found results that correlated well with our in-vitro 
experiments. Taken together these results imply a novel paradigm of vascular remodeling to 
mechanical stimuli in which net arterial remodeling is controlled by the dynamic interplay 
between pro-growth signals from vascular smooth muscle cells and anti-growth signals from 
endothelial cells. 
In a second portion of this work, we examined the role of heparanase in vascular remodeling. 
Using siRNA gene silencing and overexpression techniques, we showed that alterations in 
heparanase expression lead to a profound modulation in endothelial inhibition of vascular smooth 
muscle cell proliferation. In vivo, we quantified heparanase expression in animal models of 
hypertension, vascular disease and injury. Immunohistochemical analysis of the aortae of 
hypertensive rats revealed an increase in endothelial production of heparanase that strongly 
correlated with increased aortic structural remodeling. Studies of vascular injury with stenting in 
the Zucker rat model of diabetes showed a relationship between neointimal heparanase expression 
and lesion thickness. Our results define a new role for heparanase as a key molecular controller 
of vascular remodeling in diverse disease states. 
Thesis Supervisor: Elazer R. Edelman 
Title: Thomas D. and Virginia W. Cabot Professor, Division of Health Sciences and Technology 
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Chapter 1 : Introduction 
The vascular endothelium is comprised of a single layer of cells situated between 
the blood and the solid tissues of the body. In recent years, this thin layer of cells has 
been shown to be a dynamic constituent of the vascular system, exerting remarkable 
control over such diverse process as hemostasis, inflammation, and regulation of vascular 
tone. As a consequence of its unique location, the vascular endothelium is exposed to a 
distinct mechanical environment consisting of hemodynamic shear stress and mechanical 
stretch from blood pressure. Vascular homeostasis requires that endothelial cells must 
respond to their mechanical environment and regulate appropriate changes in arterial 
structure. In this work, we examine the role of heparan sulfate proteoglycans in the 
control of vascular remodeling. 
Previous work has found that heparan sulfate proteoglycans are powerful, 
ubiquitous sensors of cardiovascular injury and mediators of cardiovascular health. 
These complex molecules are composed of a core protein covalently coupled to one or 
more heparan sulfate glycosaminoglycan chains. The heparan sulfate chains consist of a 
linear polymer of alternating disaccharide units heterogenenously modified by 
epimerization, deacetylation, and sulfation[l] to create an intricate molecular structure 
with an information capacity far exceeding that of nucleic acids [2]. Heparan sulfate is 
known to interact with a wide variety of proteins ranging from growth factors and 
cytokines to various enzymes and extracellular matrix molecules [3,4]. 
Endothelial cells are known to be the major source of extracellular HSPG in 
arteries. The large extracellular proteoglycan perlecan has been has been shown to be a 
potent inhibitor of vascular smooth muscle cell proliferation [5] and a key component in 
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endothelial control of vSMC proliferation[6]. In addition to perlecan, endothelial cells 
and vSMCs express several cell surface HSPG including transmembrane proteoglycans 
syndecan-1, -2, and -4 as well as glypican-l[7]. The syndecans have been shown to be 
important in stabilizing the binding of FGF-2 to the FGFR and serve as a low affinity 
receptor for FGF capable of independent signaling[8-1 01. In addition, the syndecans also 
have an emerging role in cell adhesion, cytoskeletal arrangement, and intracellular 
signaling [ 1 11. 
In this thesis, we examined heparan sulfate proteoglycan homeostasis as major 
mechanism of endothelial regulation of arterial vascular remodeling. We first examined 
the role of mechanical forces in regulating the endothelial inhibition of vSMC 
proliferation and explored two potential mechanisms including the regulation of heparan 
sulfate proteoglycans and activation of TGF-B 1 under mechanical strain condidtions. 
Through these studies we discovered that autocrine TGF-B 1, ERK112 and p38 MAPK 
were required for the increased production of perlecan induced by mechanical strain. 
Further we examine the aortae of hypertensive animals and immunostained for various 
components suggested by our in-vitro work. 
While heparanase has received much attention as an enzyme involved in 
angiogenesis and cancer metastasis, its role in macrovascular disease and remodeling is 
relatively unexplored. To examine the role of heparanase expression in the vascular 
system we developed methods to knock-down and overexpress heparanase in endothelial 
cells. Further we examined heparanase expression in several models of vascular disease 
and injury. Our results supports the hypothesis that heparanase represent a key control 
point of vascular remodeling in diverse disease states. 
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Chapter 2: Background 
Vascular Wall Mechanics and Remodeling 
A short review of vascular 
anatomy is essential in understanding the 
mechanics of large vessels. The aorta is 
an elastic artery consisting of three major 
layers: the tunica intima, the tunica media 
and the tunica adventitia (shown in Figure 
1 [I 21). In non-injured, non-diseased 
arteries the intima consists of the 
endothelium and its underlying basement 
membrane. In injury and disease, vascular 
smooth muscle cells and immune cells 
migrate to form the neointima. The media 
consists of vascular smooth muscle cells Figure 1. Histologic slide of typical arterial 
structure [12]. 
and organized layers of elastin known as the elastic laminae. These laminae give the 
aorta its characteristic elastic properties. The adventitia is composed of collagen and 
elastin with the appearance of loose connective tissue. 
The vascular system is unique in its function of maintaining the regulated 
separation of blood components from the solid tissue of the body. As a consequence of 
this unique location, blood vessels are exposed to hemodynamic stresses from blood flow 
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and pressure. On the simplest level the artery can be considered an isotropic thin-walled 
vessel, leading to the familiar constitutive relationship: 
where q, is hoop (circumferential) strain, is hoop stress, p is transmural pressure, E is 
Young's modulus, r is vessel radius, and t is vessel thickness. In actuality, the stress- 
strain relation in arteries must account for the vessel anisotropy, vascular smooth muscle 
tone, and nonlinear elastic relations of vessel components [13]. Vascular cells are also 
subjected to wall shear stresses resulting from fluid flow. The simplest model of vascular 
flow would be to assume laminar, steady fluid flow governed by Poiseuilles Law (shown 
in Figure 2 below) with a parabolic fluid velocity regime. Actual fluid flow in arteries is 
made more complex by pulsatility, alterations in viscosity with fluid velocity, and the 
elasticity of the arterial wall. 
Range of Wall Shear Stress Magnitude 
Shear Stress, dyne/cm2 
Figure 2. Shear stress in the vascular system A) simplified view of the arterial shear stress 
profile. B) Magnitude of shear stress in various vascular conduits [12]. 
Page 16 
Vascular remodeling represents both a normal healthy response to the body's 
changing hemodynamic needs and an underlying mechanism fundamental to most 
vascular disorders. There is a spectrum of vascular response depending on the stimulus 
and underlying disease processes (illustrated in Figure 3). While various cell types can 
participate in the remodeling process, endothelial cells are particularly well positioned to 
control these processes. Endothelial cells are able to control vascular tone, smooth 
muscle cell growth, immune cell adhesion and invasion, and are directly exposed to the 
hemodynamic and chemical milieu of the blood. Thus these cells are optimally situated 
as both sensors and effectors of the vascular remodeling process [14]. 
Shear stress from fluid flow is a powerful modulator of arterial remodeling. The 
vascular system normally maintains a shear stress of about 10- 15 dynes cm'  on the 
vascular wall regardless of location within the vascular tree [15]. One model used to 
CONCENTRIC ECCENTRIC PATHOLOGIC 
Hy~erPlasia/HyPertro~y Matrix Alignment Healing 
Figure 3. Types of vascular remodeling (adapted from [14]). 
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study this phenomema is the arteriovenous fistula which allows the flow rate to be 
increased by a factor of 8 within an artery. In response to this stimulus the vessel 
remodels by increasing its diameter, both through vascular smooth muscle cell relaxation 
and matrix remodeling involving matrix metalloproteases (MMPs) [16]. Blood pressure 
causes circumferential stress on the artery and likewise has a strong influence on arterial 
remodeling. Similar to shear stress, the physiology of the body maintains an 
approximately constant value (around 2. lo6 dynes cm") of circumferential stress 
independent of location in the arterial tree. The vessel maintains this stress by regulating 
the thickness of the artery through vascular smooth muscle hypertrophy, proliferation and 
matrix synthesis [ 151. 
Clinically, arterial stiffhess increases with age and various disease states. These 
disease states themselves are associated with increased cardiovascular risk, so a 
fundamental question is whether stiffhess is a marker or a direct causal agent in the 
development of vascular disease [17]. Recent studies have shown that components of the 
extracellular matrix can directly affect the development of hypertension, supporting a 
direct role for arterial stiffhess in modulation of blood pressure [18]. 
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Vascular Cell Mechanotransduction 
Underlying the vascular response to mechanical stimuli is the fundamental 
biochemical mechanisms that govern the ability of cells to sense and respond to 
mechanical stimuli. Molecular mechanisms of cell signaling in response to mechanical 
stimuli have been the subject of an extensive amount of research (reviewed in [19] and 
[15]). Many receptors have been found to be responsive to mechanical stimuli in 
vascular cells (shown in Figure 4). One of the receptor types that has become 
synonymous with cell adhesion and mechanotransduction is the integrin family of 
receptors. These cell surface molecules exist as a dimer of an a and subunit. Each of 
these pairings has a binding target in the extracellular matrix (e.g. a5P1 for fibronectin). 
Integrins can become activated by binding their respective ligand and clustering. When 
activated, integrins bind into a focal adhesion complex consisting of several proteins 
11 - lull hmnwt I 
Figure 4. Molecular mechanisms of mechanotransduction [I 51. 
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including vinculin, talin and a-actinin (Figure 5) [20]. When cells are stimulated with 
mechanical force, integrin clustering leads to activation of focal adhesion kinase (FAK) 
[2 1-23lthrough c-Src [24]and possibly Rho A [25,26]. Many studies support the 
involvement of mitogen-activated protein (MAP) kinase cascades in the 
mechanotransduction process. Cyclic stretch has been shown to activate ERK112 and 
JNK pathways in vascular smooth muscle cells both in-vitro [27] and in-vivo [28]. The 
p38 MAPK has also been implicated in the response to cyclic stress [29] and fluid shear 
stress [30]. The mechanistic step between FAK activation and MAPK or other cell 
signaling pathways remains elusive. Many pathways have been implicated but are highly 
dependent on the model of mechanical load being used. These include activation of G 
Ten si, , 
Figure 5. Molecular components of a focal adhesion complex [20]. 
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proteins [19,3 11, receptor tyrosine kinases [32], epidermal growth factor receptor [33] 
and generation of reactive oxygen species [29]. 
Multiple transcription factors have been implicated in the response of vascular 
cells to stretch and shear stresses. Elevated activity of NF-KB and associated genes has 
been found in-vitro and in regions of disturbed flow in-vivo [34,35]. The transcription 
factor KLF2 has also been implicated in flow response and proinflammatory activation 
[36,37]. Depending on the load conformation and cell type, other transcription factors 
have been found to be involved in the regulation of mechanosensitive genes including 
Egr- 1, Sp 1 [3 8-40], and members of the AP- 1 family [4 11. 
TGF-ff in the Vascular System 
In this thesis we examine the role of transforming growth factor beta (TGF-p) in 
the mechanotransduction process and the control of heparan sulfate proteoglycan 
production. Transforming growth factor beta (TGF-p) is a cytokine with diverse 
functions including the regulation of proliferation, differentiation and survival of many 
cell types [42]. Specifically, TGF-p has been shown to play an essential role as a 
modulator of angiogenesis [43,44], tumor growth [45,46], and many diseases [47,48]. 
A defect in TGF-p signaling has been linked to a hereditary vascular disorder known as 
Hereditary Hemorrhagic Telangiectasia or HTT [49,50]. 
TGF-p is disulfide linked homodimeric protein that is made in latent form and 
activated by cleavage of a C-terminal polypeptide. This cleavage can occur through 
multiple mechanisms including proteolytic cleavage by MMPs or plasmin [5 1,521, 
interaction with thrombospondin [53], integrins [54], reactive oxygen species [55], low 
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pH [56] or heparan sulfate [57]. TGF-6 signaling occurs through a heteromeric complex 
of transmembrane serinelthreonine receptors (shown in Figure 6). This complex consists 
of a high affinity type I1 receptor which binds to TGF-6 and then recruits a type I 
receptor leading to autophosphorylation of the type I receptor and Smad proteins [58, 591. 
Smads are the classical downstream effectors of TGF-6 signaling and the question of 
how these molecules regulate specific genes is the subject of active research [60]. Smads 
alter transcription through several mechanisms. Firstly, Smads can form a heterotrimeric 
complex which can translocate to the nucleus and serve directly as a transcription factor 
[5 8 ,6  11. Smads can also affect transcription through Smad interacting transcription 
factors. These transcription factors have high affinity to a specific sequence of DNA in 
the gene regulatory region. Smad 2 through 4 have been shown to bind DNA with a less 
stringent sequence requirement than typical transcription factor and can consequently 
serve to enhance gene transcription if an appropriate Smad-binding region is in proximity 
to the binding sequence of the interacting transcription factor [58, 591 (for a summary of 
interacting transcription factors see [60]). Of particular interest to this work is the fact 
that when Smad 3 interacts with Spl and c-Jun the binding affinity of these factors 
increases [62,63]. Smad-Sp 1 interactions have been show to activate TGF- p induced 
genes including PAI- 1, collagen, integrin 65, and Smad 7 [60]. 
Other signaling pathways have also been implicated in TGF-p signaling. 
Specifically, TGF-6 has been shown to activate ERK [58, 591 and p38 MAPK [64]. 
Cross talk occurs through a signaling intermediate interaction with the Smads in the 
MAPK, Akt, JNK, and cyclin dependent kinase signaling networks (reviewed in [60]). 
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Figure 6. TGF-p Signaling Pathway [60]. 
Heparan Sulfate Proteoglycans in the Endothelial Control of 
Vascular Smooth Muscle Cell Biology 
In order to control vascular remodeling, endothelial cells secrete a number of 
compounds that modulate smooth muscle cell growth and proliferation. In this work we 
examined heparan sulfate proteoglycans and TGF-p, two potent modulators of vascular 
smooth muscle that have been shown to interact and underlie endothelial inhibition of 
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smooth muscle cell proliferation. In culture, postconfluent endothelial cells inhibit 
vascular smooth muscle proliferation whereas subconfluent cultures do not [65-691. 
Heparin and heparan sulfate have been shown to inhibit neointimal proliferation in 
animal models of vascular injury and disease [70-751. This inhibition is dependant on 
heparan sulfate proteoglycans but also requires a protein component [6]. In this section 
we review the relevant aspects of heparan sulfate proteoglycans and their role in the 
vascular system. 
Heparan Sulfate Proteog lycans 
Heparan sulfate proteoglycans consist 
core protein covalently linked to one or more 
heparan sulfate gl ycosaminogl ycan chains. The 
heparan sulfate chains consist of a linear polymer 
of alternating disaccharide units heterogenenously 
Figure 7. Molecular structure of heparan 
modified by epimerization, deacetylation, and sulfate glycosarninoglycan chain [76]. 
sulfation [I] to create an intricate molecular structure (shown in Figure 7) with an 
information capacity far exceeding that of nucleic acids [2]. Heparan sulfate is known to 
interact with a wide variety of proteins ranging from growth factors and cytokines to 
various enzymes and extracellular matrix molecules [3,4]. In particular, its structure is 
similar to that of the common anticoagulate drug heparin, but is less modified by 
sulfation. 
The synthesis of HSPGs is complex and not fully understood. Proteins are 
targeted for glycoslysation in the transgolgi by having a particular amino acid sequence 
Ser-Gly (A1a)-X-Gly (Ala). This site accepts an initial tetrasaccaride synthesized by four 
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Figure 8. The biosynthesis of heparan sulfate [77]. 
enzymes [78]. Heparan sulfate synthesis is initiated by the heparan sulfate copolymerase 
that adds glucuronic acid and N-acetylglucosamine to produce the initial heparan sulfate 
structure (Figure 8). This initial chain is then heterogeneously modified by deacetlyation, 
epimerization and sulfation to create a intricate fine structure [79]. 
In the vascular system heparan sulfate is found on several core proteins including 
the perlecans, glypicans, and syndecans. Perlecan is a large heparan sulfate proteoglycan 
found in the basement membrane. In humans it is the product of the HSPG2 gene with a 
molecular weight of 470 kDa and approximately 800 kDa after post-translational 
glycoslyation [3]. It has a modular structure possessing a myriad of interactions with 
growth factors, extracellular matrix molecules and adhesion molecules (Figure 9). Its 
name is derived from its "pearls on string" appearance under rotary shadowing electron 
microscopy [80]. In the vascular system perlecan has been shown to have a role in 
angiogenesis, atherosclerosis and vascular injury [5, 8 11. 
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Figure 9. Structural domains of perlecan [3]. 
The syndecans are a family of transmembrane heparan sulfate proteoglycans 
found on the cell surface and shed in a soluble form (reviewed in [77]). Each syndecan 
consists of an extracellular domain that contains glycosaminoglycan attachment sites, a 
single pass transmembrane domain, and a short cytoplasmic domain with multiple 
phosphorylation sites. The heparan sulfate and chondrointin sulfate glycosaminoglycan 
chains allow syndecans to interact with a large number of ligands including FGF-2, 
VEGF, PDGF and TGF-fl [ l  11. The interaction of syndecans with FGF-2 is probably the 
most characterized of these interations. Syndecans and the attached heparan sulfate 
proteoglycan are essential for effective binding and signaling of the FGF receptor [82]. 
On the cell surface syndecans stabilize the FGF-2lFGFR complex and are essential for 
effective signaling [82]. When shed from the surface, syndecan-1 can inhibit FGF-2 
induced cell proliferation [83]. However, physiologic degradation of syndecan by 
heparanase may lead to heparan sulfate fragments that enhance FGF-2 signaling [84]. 
Syndecan-4 has also been shown to interact with FGF-2 and promote FGF-2 signaling 
[9]. Recent work has also found that syndecans can act independently of the FGF 
receptor to act as a transmembrane receptor of FGF [8]. 
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Transforming growth factor-p (TGF-p) has been shown to interact with the 
heparan sulfate chains on syndecans. Syndecan-2, in particular, has been shown to 
interact with TGF-p via a protein-protein interaction [85]. The exact nature and role of 
this interaction is complex and still remains to be elucidated. The presence of syndecan-2 
may serve to compete with betaglycan (TGF receptor type 111) for the binding of 
synectin. Synectin stabilizes betaglycan on the cell surface and, consequently, syndecan- 
2 may serve to reduce signaling in the TGF pathway [ l  1, 851. 
The syndecans have an intricate role in orchestrating development and are known 
to be involved in cell-cell and cell-matrix adhesion. Syndecan-1 has been shown be 
important for cell adherence to type-I collagen [86]. In addition, syndecan- 1 stabilizes 
the interactions of vitronectin with avp3 integrin [87]. During migration syndecan- 1, 
syndecan-4 and calveolin are directed to the region of cell contraction [88-901. 
Syndecan-4 has also been shown to be an essential component for the activation of focal 
adhesion kinase and is known to bind fibronectin with its heparan sulfate chains [91-931. 
In vascular smooth muscle cells exposed to shear stress syndecan-4 has been shown to 
dissociate from focal adhesions [94]. 
Several studies have revealed differential regulation of syndecans by various 
growth factors and cytokines. Fibroblast growth factor-2 (FGF-2) has been shown to 
increase syndecan-4 expression in vascular smooth muscle cells [95]. Arterial injury and 
myocardial infarction have also been shown to increase syndecan-4 expression [94,96, 
971. Stimulation with tumor necrosis factor-a (TNF-a) increases syndecan-2 expression 
and decreases syndecan- 1 in endothelial cells [%I. Transforming growth factor p2 
increases syndecan-4 and decreases syndecan- 1 in epithelial cells [99]. 
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Figure 10. Heparanase cleavage site within heparan sulfate and associated molecules 
released by heparan sulfate degradation [loo]. 
Heparanase in Cancer, Angiogenesis and Vascular Disease 
A major goal of this thesis is to examine the role of heparanase in vascular 
remodeling. Heparanase is an endo-beta-D-glucuronidase that cleaves at a particular site 
in heparan sulfate to create fragments that are 10-20 sugar units long and still biologically 
active [84, 10 1 - 1031 (Figure 10). While the presence of heparanase-like activity has been 
known for decades, the gene for heparanase was cloned independently by two groups in 
1999 [1O4, 1051. Tight regulation of heparanase activity is essentially due to the potential 
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tissue damage that could result from widespread HSPG degradation. The enzyme is 
synthesized as a 65 kDa zymogen which is cleaved into the active 50 kDa form [1O5]. 
The exact regulator of this process is unknown but may potentially include cytokines, 
local pH, cellular localization and a membrane bound protease [ 1 061. 
Heparanase is known to be involved in the metastasis of cancer [loo]. 
Degradation of heparan sulfate is an essential step in the extravagation of cells in the 
blood [ 107- 1 131. Heparanase expression correlates strongly with metastasis of cancers 
cells [ 102, 104, 1 10, 1 141 and heparanase inhibitors significantly reduce the metastatic 
potential of cells in experimental models [ 109, 1 10, 1 151. A recent paper has shown that 
inhibiting heparanase expression using gene silencing techniques reduced metastatic 
potential of cancer cells and inhibited tumor angiogenesis [116]. Sulfated polysaccarides 
have been shown to inhibit heparanase (as well as having other activities) and have also 
been shown to inhibit cancer metastatis [110]. 
Heparan sulfate and heparanase are also known to play an essential role in 
angiogenesis. Heparanase expression increases during endothelial cells undergoing 
angiogenesis versus mature vessels [102]. Further, wound vascularity is enhanced with 
the topical administration of heparanase [102]. The mechanism behind this relation is 
though to be the release and induction of angiogenic growth factors by heparanase [102]. 
While there exists a large body of work examining the role of heparanase in 
cancer, there are only a limited number of studies that have addressed the role of 
heparanase in macrovascular biology. Specifically, it has been shown that heparanase- 
like activity in combination with matrix metalloprotease-9 (MMP-9) is important for a 
phenotypic change in vascular smooth muscle cells induced by macrophages [117]. 
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Other studies have shown that platelet-derived heparanase can release FGF-2 from the 
extracellular matrix and lead to vSMC proliferation and migration both in-vivo and in- 
vitro [118, 1191. 
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Chapter 3: Regulation of Heparan Sulfate Proteoglycans 
by Mechanical Strain 
It is the goal of this portion of the thesis to understand some of the basic 
mechanisms that control the vascular response to hemodynamic stimuli. Mechanical 
stress has both positive and negative effects on the artery. The negative effects are 
illustrated by the clinical outcomes of hypertension including increased risk of stroke and 
myocardial infarction. Hypertension induces the production of reactive oxygen species 
and pro-inflammatory factors and has increased plaque formation in animal models [120]. 
In contrast, mechanical stress also has beneficial effects in terms of atherosclerotic 
disease. Atherosclerotic plaques are found to form more frequently in arterial regions of 
disturbed flow or low shear stress when compared to arterial regions of steady laminar 
flow [12 11. High shear stress is known to be a key mediator of this effect by inducing 
NO synthesis [ 1221 and attenuating VCAM expression [ 1231. In contrast, oscillatory 
shear stress causes endothelial cells to express cell surface adhesion molecules and 
soluble factors that enhance leukocyte recruitment [ IN].  
The specific aim of this section is to identify the role of mechanical stimuli in the 
endothelial production of inhibitory factors towards vascular smooth muscle cells. This 
aims to give insight into the fundamental mechanisms by which vascular remodeling is 
orchestrated by endothelial cells. This work was begun with a simple experiment 
directed at finding whether mechanical strain served to increase or decrease endothelial 
inhibition of vascular smooth muscle cells. After identifying two inhibitory molecules 
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that were modulated by mechanical load we then examined several potential 
mechanotransduction pathway that were responsible for regulating these alterations. 
Methods 
Cell Culture. Rat vascular smooth muscle cells (RVSMCs) and bovine aortic 
endothelial cells (BAECs) were isolated from fresh bovine or rat aortae. These cells were 
cultured in Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen, Carlsbad, CA) 
supplemented with 5% calf serum (Hyclone, Logan UT) and 100 units per ml of 
penicillin, 100 pg per ml streptomycin sulfate, and 2 mM L-glutamine. Human umbilical 
vascular endothelial cells (HUVECs, Cambrex, Walkersville, MD) were grown in 
DMEM with 5% fetal bovine serum (Hyclone) and EGM-2 supplements (Cambrex). All 
smooth muscle cells were used at passages 4 to 5 and all endothelial cultures were used at 
passages 3 to 5. All cells were incubated at 37OC in a humidified atmosphere containing 
5% co*. 
Mechanical Strain Application to Cultured Cells. The device to apply mechanical 
strain to cells has been described previously (shown in Figure 1 1 and Figure 12) [125]. 
This device was kindly loaned to us by Professor Martha Gray at MIT. Essentially, this 
device applies load by pushing a piston through the bottom of a custom culture plate with 
a flexible silastic membrane as a culture surface. A major advantage of this system over 
the commercially available Flexcell system is it creates a uniform strain field across most 
of the silastic membrane [126]. The Flexcell, however creates a heterogeneous strain 
field with both compressive and tensile regions. The maximal strains from studies using 
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this device are actually averages of this entire field. Consequently, a 20% maximal strain 
reported from this device represents a range of actual strains on cells. 
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Figure 11. Diagram of mechanical device for applying strain to cells in-vivo [127]. 
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Figure 12. Photograph of mechanical device for applying strain to cultured cells. 
We developed a notable addition to the use of this device by creating a 
manufacturing process for creating disposable cell culture inserts with silastic membrane 
culture surfaces. This allowed us to create many culture inserts and enabled simultaneous 
preparation of cell culture plates to allow faster serial runs with the mechanical loading 
device. The original culture inserts were sprayed with silicone mold release and molded 
using silicone rubber (Smooth Sil950, Smooth-On, Inc., Easton, PA). The mold was 
cured overnight and the original part cut free of the mold. The culture inserts were then 
cast using Smooth-Cast 300 polyurethane plastic and post-cured overnight at 50Â°C 0- 
rings were created using 3/32" Buna-N o-ring cord (part #ORBK-015, Small Parts, 
Miami Lakes, FL) to match the original o-rings. The silicon membranes (0.005" 
nonvulcanized rubber, gloss/gloss finish; Specialty Manufacturing, Inc., Saginaw, MI) 
were mounted into the inserts and secured using silicon sealant (Superflex Clear RTV, 
59530; Loctite, Rocky Hill, CT). The silastic membranes were sprayed twice with 70% 
ethanol and sterilized overnight under a germicidal UV lamp. The inserts were then 
coated with collagen by incubating the membranes with 10 ml of a 50 pglml solution of 
collagen I in phosphate buffered saline (BD Biosciences, San Jose, CA) containing 
penicillin and streptomycin for 48 hrs at 37OC. The membranes were then washed twice 
with PBS and endothelial cells were passaged onto the plate at a 1 :4 density from 
confluence. The cells were grown to confluence and kept in this state for 2 days prior to 
performing the experiment. Endothelial cells were grown on the collagen-coated silastic 
membranes and cyclic mechanical strain was applied with maximal strain of 3% or 5% 
and frequency of 1 Hz. 
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Metabolic labeling and Proteoglycan Isolation. At the time of mechanical loading, 100 
pCi of  SO^ and 80 pCi of '~-~lucosamine was added to each plate. After loading, the 
conditioned media was collected and combined with guanidine-HCl to a final 
concentration of 4 M. The cell layers were then washed three times with cold PBS then 
PBS with 1.0 mM EDTA was added and the cells were allowed to detach. The cells were 
spun down and washed with PBS twice and then resuspended in 1 ml of 0.05% trypsin- 
EDTA solution (Invitrogen, Carlsbad, CA) and placed on ice for 10 min. Mild trypsin 
digestion has been shown to isolate almost exclusively cell surface proteoglycans due to 
the high sensitivity of the syndecans to proteolysis [128]. After the trypsin digestion, the 
samples were centrifuged and 1 ml of DMEM with 5% CS was added to neutralize the 
trypsin. This solution was then brought to a final concentration of 4 M guanidine-HCl. 
Analysis of Proteoglycans. A diagram of the experimental procedures for the analysis of 
the proteoglycans is shown in Figure 13. Briefly, the isolated conditioned media and cell 
surface digests were desalted into Buffer A (20 mM Tris, 8 M Urea, pH = 8.0) using a 
HiTrap desalting column (Amersham Biosciences, Piscataway, NJ). The proteoglycans 
were separated from other proteins by fractionation on a 1 ml HiTrap Q ion exchange 
column (Amersham) with a linear salt gradient from 0 to 2 M NaCl. One rnl fractions 
were collected and aliquots of these samples were counted using liquid scintillation. 
Aliquots were subjected to digestion with 0.6 Ulml of protease free chondroitinase ABC 
(Seikagaku, Japan) for 4 hrs. Control samples were subjected to digestion conditions 
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without the addition of enzyme. The GAG fractions were pooled, desalted, and subjected 
to /^-elimination in 0.1 M NaOH and 1 M NaBH4 at 40 O C  for 24 hrs. The solution was 
then neutralized with 50% acetic acid and the GAGS separated from protein by Q column 
chromatography. The free GAG chains were separated by gel filtration chromatography 
on a Superose 12 column (Amersharn) using Buffer A with a flow rate of 0.4 mllml. 
Fractions were taken throughout the run using 0.5 ml fractions and were counted using 
liquid scintillation. 
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Figure 13. Flow diagram for analysis of glycosarninoglycans. C.ase = Chondroitinase. Size Excl. Chrom. = 
Size Exclusion Chromatography. Ion Exchange Chrom. = Ion Exchange Chromatography. 
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Cell Lysis and Western Blottingm Cells exposed to various treatments were placed on 
ice and washed twice with cold PBS. One ml of lysis buffer containing 20 mM Tris, 150 
mM NaCl, 1% Triton X- 100, 1% deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 
50mM NaF, 2 mM PMSF, and the standard concentration of mini-complete protease 
inhibitor cocktail (Roche, Nutley, NJ) was added to each plate. After 10 minutes of 
incubation in lysis buffer, the plates were scraped and the lysates pipetted into a 
centrifige tube. The samples were cleared by centrihgation at 14,000 g for 15 minutes 
prior to western blotting. The samples were run on 4-15% polyacrylamide gradient gels 
and transferred to PVDF membranes (Millipore, Billenca, MA). The membranes were 
blocked for 1 hr in 5% non-fat milk in PBS with 0.01% tween-20 (PBST) and exposed to 
the following antibody dilutions at 4OC overnight in 1% non-fat milk: mouse anti- 
heparanase (1 ~200; Cell Sciences, Canton, MA), mouse anti-perlecan (1 : 100; Invitrogen), 
mouse anti-Sp 1 (1 : 100; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-TGF-p 1 
antibody (product #G122A; Promega, Madison WI), an anti-phospho-Smad-2 
(Ser4651467; l38D4; Cell Signaling), rabbit anti-phospho-p3 8 MAPK (Thrl8OlTyrl82; 
12F8; Cell Signaling), and rabbit mti-phospho-p44142MAPK (Thr202lTyr204; 20Gll; 
Cell Signaling). The membranes were washed with PBST, incubated at room 
temperature for 2 hrs with a 1 :3000 dilution of a horseradish peroxidase linked secondary 
antibody (Promega), and detected using a chemiluminescent reagent (Western Lightning 
Plus; Perkin Elmer, Boston, MA). 
ELISA Measurement of TGF-pl and FGF-Zm TGF-p 1 was measured using an ELISA 
assay (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. 
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Latent TGF-pl was activated by adding 20 pl of 1 N HCl to 100 pl of sample. The 
samples were incubated for 10 minutes at room temperature and then neutralized with 20 
pl of 1.2 N NaOW0.5 M HEPES and assayed immediately. To extract FGF-2 fiom the 
extracellular matrix the cells were lysed and the culture plates washed three times with 
cold PBS. The PBS was removed and 10 ml of extraction buffer containing 2 M urea and 
2.5 mg/ml heparin in PBS was added. The plates were incubated 48 hours with rocking 
to extract the FGF-2 and then dialyzed against three changes of distilled water for 48 hrs. 
The dialysis was performed using a 3500 molecular weight cutoff membrane in a 
slidealzer cassette (Pierce Biotechnology, Rockport IL). The samples were then snap 
fiozen using liquid nitrogen, lyophilized, and reconstituted in 1 ml of PBS. Media 
samples were assayed without fbrther preparation. An ELISA assay (R&D Systems, 
Minneapolis, MN) was used to measure FGF-2 in the media and matrix extracts. 
Gene Expression Analysis by Real Time RT-PCR Cell were grown to confluence and 
exposed to mechanical loading as described above. The cells were washed twice with 
PBS and mRNA was isolated using a RNAeasy Mini Protect Kit (Qiagen, Valencia, CA) 
following the manufacturer's instructions. Homogenation of the samples was performed 
using QIAshredder columns (Qiagen). A DNase digestion was performed while the RNA 
was bound to the column using RNase fi-ee DNase (Qiagen). Reverse transcription was 
pefiormed using polyA primers (Applied Biosystems). Real time PCR was pefiormed 
using an MJ Research Real Time PCR Machine at MIT BioMicro Center (Cambridge 
MA) using a SYBR Green Master Mix (Applied Biosystems). Cycle conditions were as 
follows: 2 min at 50Â°C 10 min at 95OC, and 40 cycles of of 15 s at 94OC and 1 min at 
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60Â°C Primers used for the real time PCR were as follows: GMDH, 
GGCCTCCAAGGAGTAAGACC (sense, S), AGGGGTCTA CATGGCAACTG (anti- 
sense, AS); syndecan-1, AGGGGACAGGAGTC CACTTT (S), GGGGGATACCGMT 
CAACTT (AS); syndecan-2, CTCAAGGATGAC GTGGGTTT (S), GATTTCCTCTGG 
CCAATTCA (AS); syndecan-4, TCGATCCGAGAGACTGAGG T (S), CCAGATCTCC 
AGAGCCAGAC (AS); heparanase, ATCAATGGG TCGCAGTT AGG (S), AGGCTGA 
CCAACATCAGGAC (AS); perlecan, TCCACCTG AGTACCCG AAAC (S), CTGAAG 
TGACCAGGCTCCTC (AS). 
Smooth Muscle Cell Proliferation AssayD Rat smooth muscle cells were passaged into 
six-well plates at low density. Endothelial cell conditioned media was isolated and used 
in an assay of vascular smooth muscle cell proliferation. Smooth muscle cells were serum 
starved in 0.5% calf serum for 24 hours, washed with PBS, and incubated in conditioned 
media with 1 pCi/ml 3 ~ - t h ~ d i n e  for 24 hours. The cells were then washed three times 
with PBS at 4OC. The cells were then incubated with 10% TCA for 30 min at 4OC, washed 
twice in 95% ethanol, and solubilized in 1 ml of 0.25 M NaOH with 0.1% SDS for 1 
hour. The samples were then added to scintillation cocktail and radioactivity was 
measured using a liquid scintillation counter. 
StatisticsD All results are shown as mean 2 one standard deviation. An ANOVA was used 
to make comparisons between groups of continuous variables. A two-tailed Student's t 
test was used to make comparisons between groups; p < 0.05 was defined as being 
statistically significant. 
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Results 
Mechanical strains of 5% Maximal Strain are Not Cytotoxic to 
Endothelial Cells in Culture 
As these experiments were aimed at understanding the affects of chronic load and 
not acute injury and cell death, an experiment was performed to assess cell viability as a 
h c t i o n  of maximal strain. Lactate dehydrogenase (LDH) is an intracellular enzyme that 
is constitutively expressed by virtually all cell types. The release of this enzyme fiom the 
cell indicates that the cell membrane integrity has been compromised and that cell 
damage has occurred. The release of this enzyme in response to mechanical load was 
measured under experimental conditions at various maximal strains. In HUVEC there is 
little release of LDH into the conditioned media at I%, 3%, or 5% maximal strain (1 hz 
for 24 hrs) and a significant increase at 8% strain (see Figure 14). These results support 
that the effects of mechanical load were not fiom cell death or injury as there was no 
substantial increase in LDH release after 24 hours of load of 5% stain or less (2.6% 
2.6% increase in LDH release, n = 4). 
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Figure 14. Lactate dehydrogenase (LDH) release relative to static cultures in response to 
mechanical strain. 
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Mechanical Strain Increases Endothelial Inhibition of Vascular 
Smooth Muscle Cell Proliferation 
A fundamental question that we would like to address is whether mechanical 
strain causes endothelial cells to produce more or less inhibitory factors in response to 
mechanical stimuli. To explore the role of mechanical strain in modulating endothelial 
cell control of vascular smooth muscle cells, endothelial cells were grown on silastic 
membranes until 2 days postconfluent and then exposed to uniform, cyclic mechanical 
strain (5% maximal strain, 1 Hz) for 24 hrs. Conditioned media was harvested from 
endothelial cells under strain and non-strain conditions, and applied to vascular smooth 
muscle cells in culture. Proliferation of the vSMCs was measured using incorporation of 
radiolabeled thymidine. Cyclic mechanical strain increased the inhibitory properties of 
HUVEC conditioned media by two fold over the inhibition from non-strained HUVEC 
cultures (80% total inhibition compared to growth media; Figure 15). This effect was 
present in multiple endothelial cell types and increased with the magnitude of the load 
(Figure 16). 
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Figure 15. Inhibition of vascular smooth muscle cell proliferation by human umbilical 
endothelial cell conditioned media. "Control media" has not been exposed to endothelial 
cell. "No strain" is conditioned medium from endothelial cells that are under static 
conditions. "Five percent strain" is conditioned medium from endothelial cells exposed 
to mechanical load for 24 hrs. Results are mean + standard deviation, *p < 0.05 versus 
5% control media; * *p<0.05 versus no strain and control media; n = 5- 12. 
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Figure 16. Inhibition of vascular smooth muscle cell proliferation by bovine aortic 
endothelial cell conditioned media. Five percent calf serum is control media that has not 
been exposed to endothelial cells. No strain is endothelial cell conditioned medium (ECCM) 
from endothelial cells that are under static conditions. Three or five percent strain is 
conditioned medium from endothelial cells exposed to mechanical load for 24 hrs at either 
3% or 5% maximal strain. All comparisons have p < 0.05. 
Page 47 
Mechanical Strain Increases Production of Heparan Sulfate 
Proteog lycans 
To examine the mechanism behind the observed increase in inhibitory molecules 
we quantified the production of heparan sulfate proteoglycan core proteins in static and 
mechanically loaded cultures (5% cyclic load for 24 hrs). Western blotting for heparan 
sulfate proteoglycan (HSPG) core proteins revealed an increase in cell-associated 
syndecan-1 and -4 as well as an increase in perlecan in the conditioned medium (Figure 
17). A control for equal loading of protein was done using an antibody for p-actin. 
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Figure 17. Western blot for HSPG core proteins, heparanase and the 
transcription factor Spl from endothelial cells exposed to 5% cyclic strain for 
24 hrs. p-actin are from cell lysate samples. Perlecan is from conditioned 
medium. Results are mean + standard deviation, *p < 0.05 versus 5% control 
media; n = 3-4. 
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Real time PCR was also used to examine the level of mRNA of the genes for the 
heparan sulfate proteoglycan core proteins (Figure 18). Mechanical strain of 5% at 1 Hz 
for 24 hours also led to an increase in mRNA expression of syndecan-1 and -4, as well as 
a decrease in the expression of syndecan-2 mRNA. An increase in perlecan mRNA was 
seen but was not statistically significant. No changes in the level of heparanase mRNA 
was found. All samples were normalized to a GAPDH gene control before normalization 
to the non-loaded control. 
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No Strain 5% Strain No Strain 
* 
5% Strain 
1.8 1 1.4 1 
No Strain 5% Strain 
1 7 
No Strain 5% Strain 
No Strain 5% Strain 
Figure 18. Real time PCR analysis of alterations in syndecan gene expression. Values are 
normalized to No Strain controls. HPA = Heparanase. 
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Proteoglycans production can be regulated on multiple levels. Consequently, it is 
possible to regulate the production of the glycosarninoglycan sugar chains without 
altering the core protein production or visa versa. To investigate the effect of mechanical 
strain on endothelial heparan sulfate glycosaminoglycan (GAG) chain production, cells 
were exposed to mechanical strain and metabolically labeled using 3~-glucosamine and 
^So4. Mechanical strain induced an increase of 24% in total soluble GAG production in 
HUVECs (Figure 19 and Figure 23). A 38% increase in soluble heparan sulfate was also 
observed (Figure 20 and Figure 23). No change in cell surface total GAG was observed 
(Figure 21 and Figure 23), but a decrease in cell heparan sulfate was observed (Figure 22 
and Figure 23). The GAGs extracted from the matrix were also measured and found to 
be increased in the extracellular matrix after mechanical load. Total normalized GAGs 
and heparan sulfate GAGs increased fi-om 1 .OO+0.09 to 1.85+O.O5 and fiom 1 .OO+O.O3 to 
l.l9Â±O.O4 respectively for mechanically loaded versus non-loaded. 
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Fraction Number 
Figure 19. Total proteoglycans in endothelial cell conditioned media labeled with 3 ~ -  
glucosamine and separated by ion exchange chromatography. Samples treated with 5% strain 
(dashed line) and no strain (solid line) are shown with the applied salt gradient (dotted line) on the 
second axis. 
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Fraction Number 
Figure 20. Heparan sulfate proteoglycans in the endothelial conditioned media labeled with 'H- 
glucosamine and separated by ion exchange chromatography. Samples treated with 5% strain 
(solid line) and no strain (dashed line) are shown with the applied salt gradient (dotted line) on the 
second axis. 
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Fraction Number 
Figure 21. Total proteoglycans on the endothelial cell surface labeled with 3~-glucosa~ine and 
separated by ion exchange chromatography. Samples treated with 5% strain (dashed line) and no 
strain (solid line) are shown with the applied salt gradient (dotted line) on the second axis. 
Page 55 
Fraction Number 
Figure 22. Heparan sulfate proteoglycans on the endothelial cell surface labeled with 'H- 
glucosamine and separated by ion exchange chromatography. Samples treated with 5% strain 
(dashed line) and no strain (solid line) are shown with the applied salt gradient (dotted line) on the 
second axis. 
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Figure 23. Total and isolated heparan sulfate proteoglycans in the endothelial conditioned 
media labeled with 3~-glucosamine and separated by ion exchange chromatography (normalized 
to no strain, *comparison of p < 0.05). 
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Another potential pathway of regulation of proteoglycans is to alter the size of the 
glycosaminoglycan chains attached to the core protein. We examined the affect of 
mechanical strain on altering the hydrodynamic size of the gl ycosaminogl ycan chains. 
The size distribution of total proteoglycans in the conditioned media was not altered by 
mechanical strain (Figure 24). There were increases in both low and high molecular 
weight heparan sulfate produced in the media (Figure 25). On the cell surface the size 
distribution was unaltered for both total and heparan sulfate proteoglycans, with 
decreases in both low and high molecular weight heparan sulfate (Figure 26 and Figure 
27) 
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Figure 24. Total proteoglycans in the endothelial conditioned media labeled with H -  
glucosamine separated by size exclusion chromatography. Representative samples treated with 
5% strain (dashed line) and no strain (solid line) are shown. 
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Figure 25. Heparan sulfate proteoglycans in the endothelial conditioned media labeled with 3 ~ -  
glucosamine separated by size exclusion chromatography. Representative samples treated with 
5% strain (dashed line) and no strain (solid line) are shown. 
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Fraction Number 
Figure 27. Cell surface heparan sulfate proteoglycans on the endothelial cell surface labeled 
with 3~-glucosamine and separated by size exclusion chromatography. Representative samples 
treated with 5% strain (dashed line) and no strain (solid line) are shown. 
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Mechanical Strain Activates TGF-PI through p38 and ERK112 
Dependant Pathway 
Transforming growth factor- p (TGF-p) is another molecule intimately involved in 
the control of vascular smooth muscle cell growth as well as a regulator of extracellular 
matrix production in various cell types. This molecule is predominantly present in latent 
form that can be activated by various factors. We examined the amount of active TGF-p 
present with mechanical load in the presence of inhibitors to the MAPK and p38 MAPK 
signaling pathways. In non-loaded cultures active TGF-p was undetectable by ELISA 
(Figure 28). Following treatment with mechanical strain for 24 hrs, significant amounts 
of active TGF-p were found in the condition media. This effect was significantly 
blocked by both inhibitors to MAPK (U0126) and p38 MAPK (SB029063). Total TGF-p 
was assayed after acidification and neutralization of the conditioned media revealing 
similar amounts of total TGF-p under all conditions (Figure 29). 
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U0126 
- + rn - + = 
SB 293063 - rn + rn + + 
Figure 28. Active TGF-b in endothelial cell conditioned media after 24 hrs of mechanical strain 
or static conditions measured by ELISA assay. 
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Figure 29. Total TGF-p in endothelial cell conditioned media after 24 hrs of mechanical strain 
or static conditions measured by ELISA assay. Total TGF-b was activated by treatment with 
acid pH prior to ELISA assay. 
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Mechanical Strain Alters Extracellular Matrix Bound FGF-2 through 
p38, ERK112, and TGF-PI Mediated Mechanism 
Heparan sulfate proteoglycans are involved in many aspects of FGF-2 signaling, 
uptake and sequestration. To examine the role of mechanical strain in regulating FGF-2 
we measured FGF-2 in the condition media and extracellular matrix fractions of cells 
exposed to static and mechanical strain conditions. In the extracellular matrix, 
mechanical strain decreased the amount of FGF-2 present (Figure 30). This effect was 
blocked completely by inhibitors to MAPK (U0126) and partially inhibited by an 
inhibitor to p38 MAPK (SB 293063). In the condition media the amount of FGF-2 was 
slightly lowered due to mechanical load (Figure 3 1). Similar experiments were 
performed examining the affects of a neutralizating antibody to TGF-p on the FGF-2 
content of the extracellular matrix and conditioned media (Figure 32 and Figure 33). 
Pretreatment with a neutralizing antibody to TGF-p blocked the decrease in extracellular 
matrix associated FGF-2. 
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Figure 30. Fibroblast growth factor-2 (FGF-2) extracted from the extracellular matrix of 
endothelial cultures pretreated for 1 hr with U0126 or SB 293063 and exposed to 24 hrs of static 
or strain conditions. 
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Figure 31. Fibroblast growth factor-2 (FGF-2) in the conditioned media of culture pretreated 
with U0126 or SB 293063 for 1 hr and exposed to static or strain conditions for 24 hrs. 
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Figure 32. A neutralizing antibody to TGF-p reduces blocks the load induced decrease in 
extracellular matrix (ECM) bound FGF-2. Endothelial cells were treated with a neutralizing 
antibody for 1 hr prior to exposure to 24 hrs of 5% mechanical strain. 
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Figure 33. The content of the conditioned media is unaffected by mechanical strain or a TGF-b 
neutralizing antibody. Endothelial cells were treated with a neutralizing antibody for 1 hr prior 
to exposure to 24 hrs of 5% mechanical strain. 
Page 70 
Mechanotransduction Pathway Controlling Load-Induced Heparan 
Sulfate Proteoglycans Involves p381ERK activation and Autocrine 
TGF-PI signaling 
To examine the intracellular signaling pathways responsible for mechanical 
strain-mediated modulation of heparan sulfate proteoglycans we pretreated cells with 
inhibitors to the MAPK (MEK112 inhibitor U0126) and p38 (SB 293063) signaling 
pathways. We hypothesized that since mechanical strain induced TGF-p activation, an 
autocrine signaling from this growth factor may be an important mechanism. Following 
inhibitor or neutralization antibody treatment we used western blotting to examine the 
levels of phosphorylated signaling intermediates including phospho-Smad-2 (a 
downstream effector of TGF-p), phospho-p38 MAPK, and phospho-ERKll2 (shown in 
Figure 34). Mechanical strain activated all of these intermediates after 24 hrs of cyclic 
strain. Interestingly, there was crosstalk between each of the signaling pathways. 
Maximal Smad-2 only occurred in the absence of both inhibitors to MAPK and p38 
MAPK. Further, phosphorylation of ERKll2 and p38 MAPK was partially blocked by 
inhibitors to each of the other pathways. This suggests that these pathways are 
communicating through some type of common pathway or that the drugs have non- 
specific affects on other signaling pathways. We performed a similar western blotting 
analysis in mechanically stimulated cultures that were pretreated with a neutralizing 
antibody to TGF-p (shown in Figure 35). We also examined the role of these pathways 
in the production of the heparan sulfate proteoglycan core proteins in response to 
mechanical strain (Figure 36). The inhibitors to MAPK and p38 pathways and the 
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neutralizing antibody to TGF-b blocked the load induced increase in perlecan 
production. 
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5% Strain + + + - - rn 
U0126 - + - - + - 
SB 293063 - + - + + 
Figure 34. Western blot analysis of intracellular signaling intermediates of the TGF-p, MAPK, 
and p38 MAPK pathways. Cells were pretreated with the indicated inhibitors for 1 hr prior and 
during exposure to static or mechanical strain conditions for 24 hrs. 
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Figure 35. Western blot analysis of intracellular signaling intermediates of the TGF-p, MAPK, 
HPA, Cell 
Perlecan 
Syndecan 4, Cell - - "-amuml--.- 
p-actin, Cell dmlmm amulmF- 
5% Strain + + + - - -  
SB-239063 ( ~ 3 8 )  + - - + -  
U-0126 (MEK) - +  - -  + 
5% Strain + + - - 
Anti-TGF-pl - + - + 
Figure 36. Western blot analysis of heparan sulfate core proteins and heparanase* Cells were 
pretreated with the indicated inhibitors or neutralizing antibody for 1 hr prior and during 
exposure to static or mechanical strain conditions for 24 hrs. 
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Promoter Analysis of Heparan Sulfate Proteoglycan Core Proteins 
and Heparanase 
A promoter analysis was performed on the various genes using PROSCAN (v. 
1.7). This analysis revealed several common transcription factor binding sites found in 
the syndecan- 1, 4y perlecany and the heparanase promoter region. Notably, a Sp 1 binding 
site was found in the promoter region of all the genes. To test whether Spl was regulated 
by mechanical strainy Spl expression was found to be increased in measurements by 
Western blotting (Figure 17). 
Inhibition of Transcription Factor Spl Leads to Maladaption of 
Endothelial Cells to Mechanical Strain 
To examine the role of Spl in the response to mechanical strain cells were 
incubated with mithramycin for 1 hr prior to mechanical loading for 24 hrs. Mithramycin 
is an antibiotic that has been used to treat certain cancers [129]. The drug binds to CG- 
rich regions of the DNA and prevents the binding of Sp 1 [ 1301. Pretreatment of cells 
with mithramycin led to an increase in cell damage due to mechanical loading. Both cell 
attachment (Figure 37a) and LDH release in the media (Figure 37b) were observed as a 
result of mechanical strain on mithramycin treated cultures. The conditioned media and 
cell lysates were analyzed for perlecan and heparanase expression revealing a decrease in 
both perlecan and heparanase in the mithramycin treatedy non-loaded cells (Figure 38). 
An increase in both perlecan and heparanase was found in the treated, loaded cell (Figure 
38). 
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Figure 37. Mithramycin and mechanical load together cause cell detachment and lactate 
dehydrogenase (LDH) release. (a) Phase contrast microscopy of cells treated with combinations of load 
and mithramycin. (b) Total LDH release into culture media of treated cell cultures (normalized to no 
strain controls). 
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HPA, 
Perlecan, Media 
Figure 38. Control of perlecan and heparanase (HPA) expression by mechanical 
strain in mithramycin treated cells. 
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Discussion 
An initial control experiment revealed that mechanical strains of 5% or less for 24 
hrs did not cause cytotoxicity. This is an important control not only for the interpretation 
of our experiments but also those present in the literature. Papers in the literature 
routinely report strain levels of 20% or more using the Flexcell system without measuring 
cytotoxicity. As a consequence these studies may be looking at an injury response of the 
endothelial cells rather than a physiologic response to increased hernodynamic stimuli. 
We began our studies with an experiment examining the role of physiologic 
loading on endothelial inhibition of vascular smooth muscle cell proliferation. In humans 
the maximal strain, in the aorta varies along the aorta fiom around 18% in the ascending 
aorta to 4- 1 5% in the abdominal aorta [ 1 3 1, 1321. With chronic hypertension or diabetes 
this strain can decrease by 40-60% due to arterial stiffening [13 11. Our studies revealed 
that mechanical strain increased endothelial production of inhibitory factors towards 
vascular smooth muscle cells. Heparan sulfate proteoglycans have been shown to be an 
essential component of endothelial inhibition of vascular smooth muscle cells [6]. A 
major question is the source of the additional heparan sulfate proteoglycan found in the 
media. The studies quantifjmg the mRNA levels in mechanically strained cells would 
indicate that the syndecans are transcriptionally regulated but heparanase and perlecan 
are not. Notably, multiple studies have shown heparan sulfate proteoglycan core proteins 
are known to show alterations in protein level without alterations in mRNA [77]. In one 
study a 10-fold change in protein was observed without a change in mRNA levels [133]. 
Various forms of post-transcriptional regulation may act on these genes as well as 
potential alterations in protein stability or degradation. 
Page 79 
The presence of additional perlecan is likely due to increased production rather 
than purely release from the extracellular matrix. Our studies on FGF-2 binding to the 
matrix indicate a reduction in bound FGF-2 to the extracellular matrix but our 
measurements of heparan sulfate in the matrix show increased heparan sulfate. The 
growth medium used in these experiments was complete growth medium containing 
serum and FGF-2 supplements. As a consequence there is likely an excess amount of 
FGF-2 in the growth media and this could saturate any potential binding sites for FGF. 
Perlecan is the major heparan sulfate proteoglycan in the endothelial extracellular matrix 
[3]. Heparan sulfate proteoglycans are the primary binding site for FGF-2 in this type of 
extracellular matrix [134]. These results are somewhat paradoxical unless we consider 
that the endothelium is acting as a barrier layer (after reaching confluency) preventing 
media FGF-2 binding to matrix. This would imply that the endothelium is increasing 
FGF-2 uptake from the matrix in response to load and would also be consistent with our 
observation that the FGF in the conditioned media remains constant. Syndecan-4 has 
been shown to be important in the endocytosis of FGF-2 and the increased FGF-2 uptake 
by the cell may be result of increased cell surface syndecan-4 [135]. 
Another potential source of increased vascular smooth muscle cell inhibition is 
the increased shed syndecan-1 observed as a consequence of mechanical strain. Shed 
syndecan-1 has been shown to be an effective inhibitor of FGF-2 signaling [84]. 
Syndecan-1 was found to be upregulated transcriptionally and on the cell surface by 
western blotting. Cell surface syndecan-1 has been shown to be important for the 
adhesion to collagen type-I [86]. The silastic membrane used in these experiments were 
coated with type-I collagen and these results would be consistent with the idea that the 
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cells were increasing the strength of attachment to this substate in response to mechanical 
load. A similar argument could be made for the upregulation of syndecan-4 that was 
observed as well. Mechanical strain has been shown to increase formation of focal 
adhesions and stress fibers [15]. Sydnecan-4 is intimately involved in these processes 
and has been shown to respond to stretch and injury in vascular smooth muscle cells [94]. 
Heparanase has also been shown to act as an adhesion molecule by binding to cell surface 
heparan sulfate proteoglycans independent of its enzymatic activity [136]. The 
syndecans can bind heparanase and may act synergistically to allow the cells to properly 
alter their adherence to the substratum to allow cell survival under loading conditions. 
The activation of TGF-p observed in response to mechanical load could also serve 
to inhibit vascular smooth muscle cell proliferation. Active TGF-p has been shown to 
regulate vascular smooth muscle growth and may act as either an inhibitor or an 
stimulator depending on the growth state of the cells [137, 1381. Heparan sulfate has 
been shown to facilitate the activation of TGF-p [57] and the increased cell surface 
proteoglycans and extracellular heparan sulfate may play a role in this process. It is also 
interesting to note that MMP-2 activation is enhanced by syndecan- 1, giving another 
potential role to the regulation pattern observed for the syndecans [139]. The syndecans 
can also function as regulators of growth factor response and transmembrane signaling 
[l 11. Syndecan-2 interacts with TGF-p via a protein-protein interaction but the exact 
nature and purpose of this interaction is unclear [85]. Studies have shown that the type 
I11 receptor for TGF-p (betaglycan) is stabilized in the membrane by synectin. Syndecan- 
2 competes for binding to synectin and may disregulate TGF-p signaling [ 1 1, 851. Our 
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results show a reduction in mRNA for syndecan-2, implying that the cell may have an 
increases sensitivity and response to TGF-p stimulation. 
Our in-vitro studies also indicate a role for the transcription factor Spl in the 
response to mechanical strain. Inhibition of Spl binding led to sensitization of the cells 
to load. Spl binding sites (GC boxes) are located in the promoter regions of 
heparanase[l40], perlecan[14 11, syndecan- 1 [142], and syndecan-4[143]. Endothelial Sp 1 
phosphorylation and DNA binding has been shown to be increased in response to fluid 
shear stress[144], and, in our work, the total Spl increased with mechanical strain. We 
show here that inhibition of Sp1 leads to maladaptation of endothelial cells to mechanical 
strain leading to cell damage and detachment. This result highlights the critical nature of 
Spl activation in controlling the cell response to mechanical strain. While many genes 
have Spl transcription factor binding domains in their promoter regions, our work shows 
that the syndecan core proteins are highly responsive to mechanical stimuli. The 
transcription factor Spl and TGF-p induced Smads have been shown to interact and 
facilitate gene transcription [62] and may present a model of regulation for the heparan 
sulfate proteoglycan protein increase observed in these studies. Another potential 
mechanism is the regulation of the Kruppel-like factor (KLF) family of transcription 
factors that has been shown bind sequences similar to Spl and has been shown to be 
important for response to mechanical stimuli [145]. 
A major contribution of this work is the elucidation of the mechanotransduction 
pathway governing the response of heparan sulfate proteoglycan to mechanical strain. 
Our results indicate that optimal stimulation of MAPK requires p38 signaling and 
autocrine TGF-p. Similarly, optimal p38 MAPK signaling requires MAPK and autocrine 
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TGF-p. Finally, TGF activation and stimulation of phospho-Smad-2 is partially blocked 
by inhibitors to both of these pathways. These results taken together suggest a signaling 
model in which MAPK and p38 are important for activation of TGF-fl and that TGF-p is 
important for the continued stimulation of MAPK and p38 pathways. Our experiments 
also suggest that this autocrine TGF-p signaling loop controls the increase in perlecan 
observed in response mechanical strain. 
An overall model suggested by this work is shown in Figure 39. In this model a 
TGF autocrine signaling loop controls the response of cells through controlling heparan 
sulfate proteoglycan production. There is also some synergistic feedback in the system 
from the heparan sulfate proteoglycans acting to facilitate TGF activation and signaling 
potentially through MMP-2, heparan sulfate binding and downregulation of syndecan-2. 
Prior work has shown that mechanical stimuli may increase vascular smooth muscle cell 
proliferation through multiple mechanisms [ 127, 146- 1481. Taken along with previous 
studies, our work fills in the endothelial side of a dynamic equilibrium which controls 
vascular remodeling to load. Explicitly, mechanical strain stimulates vascular smooth 
muscle cells to proliferate while in causing endothelial cells to increase their inhibition. 
These two processes lead to a balance between growth and inhibitory processes that can 
control vascular homeostasis. In hypertension, this increased activity would make the 
artery more vulnerable to disease processes that causing endothelial dysfunction. In this 
case the endothelial side of the balance would be compromised leaving the vascular 
smooth muscle cell growth uncompensated by endothelial inhibition. 
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Figure 39. Overall mechanistic scheme of endothelial control of vascular remodeling to 
mechanical stimuli. This study supports the signaling network outlined underneath the 
endothelial cell portion of this scheme. 
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Conclusion 
In this chapter, we gave evidence for a unified model of vascular response to 
mechanical forces in which mechanical stimuli enhanced both endothelial inhibition and 
vascular smooth muscle cell proliferation. We given evidence that supports that 
underlying the endothelial side of this balance is the regulation of heparan sulfate 
proteoglycans by an autocrine signaling loop consisting of TGF-p as well as the MAPK 
and p38 signaling pathways. In the next chapter we explore this model farther in-vivo in 
an animal model of hypertension. 
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Chapter 4: Role of Heparan Sulfate Proteoglycans and 
Heparanase in Spontaneously Hypertensive Rats 
Introduction 
Table 1. Classification of Blood Pressure in Adults 
Hypertension, or elevated blood BP Classification SBP DBP 
(-g) (mmHg) 
pressure, is the most common primary Normal 4 2 0 -  and <80 Prehypertension <120-139 or 80-89 
sttge 1 140-159 or 90-99 
diagnosis in the United States affecting Hypertension 
Stage 2 > 160 
- Or > 100 
about 50 million people in the country and Hypertension 
BP, blood pressure; SBP, systolic blood pressure, DBP, diastolic blood pressure. 
1 billion people worldwide [149, 1501. Hypertension is classified into stages based on 
systolic (SBP) and diastolic blood pressure (DBP) as shown in Table 1 (adapted from 
[15O]). A strong relationship exists between blood pressure and heart attack, heart 
failure, stroke and kidney disease. Each increment of 20 mmHg in systolic blood 
pressure or 10 mmHg in diastolic blood pressure doubles the risk of cardiovascular 
events [15 11. 
In the previous chapter, a set of experiments were performed that gave rise to a 
model of vascular response to mechanical strain. The aim of this section is to take this 
model developed in in-vitro and examine its relevance in the spontaneously hypertensive 
rat model of hypertension. To this end, we examined the expression of heparan sulfate 
proteogl ycans, heparanase, TGF- and the phosphorylat ed intracellular signaling 
intermediates Smad-2, ERIC112 and p38 MAPK in hypertensive and normal rats. 
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Materials and Methods 
Animal Model of Hypertension. All experimental procedures and protocols used in this 
investigation were reviewed and approved by the Animal Care and Use Committee of the 
Massachusetts Institute of Technology and conformed to the "Guiding Principles in the 
Care and Use of Animals" of the American Physiological Society and the NIH Guide for 
the Care and Use of Laboratory Animals. Age matched Wild-Type Wistar-Kyoto Rats 
and Spontaneously Hypertensive (SHR; NTac:SHR) rats were obtained from (Taconic, 
Germantown, NY). At 20 weeks of age the animals were sacrificed and the aortae were 
harvested. A total of 16 rats from each group were used in these experiments. 
Immunohistochernistry. The abdominal aortae from hypertensive rats were formalin 
fixed and sectioned using standard methods. The sections were heated for 10 min in a 
60Â° oven, deparaffinized in xylene, and rehydrated. Antigen retrieval was performed by 
placing the slides in 1 OmM citrate buffer (pH = 6.0) and heating in the microwave for 10 
min. The samples were allowed to cool for 20 min and were then incubated in 3% 
hydrogen peroxide for 1 0 min. The samples were rinsed 3 times with PBS with 0.0 1 % 
tween-20 (PBST) between each of the following steps. The sections were blocked with 
20% normal goat serum for 45 minutes at room temperature. For staining of heparan 
sulfate proteoglycans the slides were treated for 2 hrs with a 0.4 Ulml solution of 
heparitinase I11 (Ibex, Canada). Primary antibodies were diluted in PBS containing 1% 
BSA, applied to slides, and incubated in a humid chamber for overnight at 4Â°C The 
following antibodies were used for staining: an anti-heparanase (Cell Sciences, Canton, 
MA); a monoclonal antibody recognizing "stubs" of digested heparan sulfate (3GlO; 
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Seikagah); an anti-TGF-p 1 antibody (product #G122A; Promega, Madison WI); an anti- 
phospho-Smad-2 (Ser4651467; 138D4; Cell Signaling); an anti-phospho-p38 MAPK 
(Thr 1 8OlTyrl82; 1 2F8; Cell Signaling); anti-phospho-p44142MNK (Thr202lTyr204; 
20Gll; Cell Signaling); and anti-sp 1 (1 C6; Santa Cmz Biotechnology). Secondary 
antibody staining at detection was performed using the LSAB 2 kit (DakoCytomation, 
Carpinteria, CA) according to the manufacturer's instructions. An AEC substrate 
(DakoCytomation) was used for detection of the horseradish peroxidase conjugate. The 
samples were counterstained in Mayer's hematoxylin for 3 min, washed with tap water, 
and mounted in aqueous mounting mediurn (DakoCytomation). M e r  24 hrs the sections 
were mounted and coverslipped with Cytoseal XYL (83 12-4; Richard Allen Scientific, 
Kalamazoo, MI). 
Quantitative Morphology. To quantify the irnmunohistochemical staining the sections 
were first imaged using an Olympus BX41 (Olympus, Melville, NY) with a DP70 CCD 
(Olympus). The images were captured using Microsuite Biological Suite 2.4 (Olympus). 
The images were quantified using Photoshop (Adobe Systems, Inc., San Jose, CA). To 
perform the quantitation of DAB or AEC substrate staining, the region of interest was 
selected using the magic wand tool in Photoshop (Adobe). The average intensity of each 
color channel was recorded (red, green, or blue) and number of pixels (area) were taken 
using the histogram hct ion .  A similar reading was taken for the background (white 
field) of each captured picture. The optical density (OD) was calculated using the 
following equation: 
Page 88 
Where I is the color channel intensity and I. is the color channel intensity of the 
background. A deconvolution matrix to separate DAB or AEC and hematoxylin staining 
was calculated using the method of Ruifiok and Johnston [ 1521. These matrices were 
used to separate the hematoxylin staining fiom imunostaining and give an overall 
density of staining within the region of interest. 
Statistics. All results are shown as mean standard deviation. An ANOVA was used to 
make comparisons between groups of continuous variables. A two-tailed Student's t test 
was used to make comparisons between groups; p < 0.05 was defined as being 
statistically significant. The Pearson product moment correlation statistic was used as a 
measure of correlation between variables. 
Results 
Hypertension Increases Heparan Sulfate Proteoglycan and 
Heparanase Expression in the Endothelium of Spontaneously 
Hypertensive Rats 
To evaluate the role of heparan sulfate proteoglycans and heparanase in 
modulating arterial remodeling in hypertension, we examined the expression of heparan 
sulfate proteoglycans and heparanase in the spontaneously hypertensive (SHR) rats 
compared with age-matched Wistar-Kyoto (WKY) wild-type rats. Formalin fixed, 
paraffin embedded sections were made fkom rat aortae fkom each group. The sections 
were stained with hematoxylin and eosin and analyzed morphologically. This analysis 
revealed increased medial thickening in the medial region of the SHR rat aortae (Figure 
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40). The expression of total heparan sulfate proteoglycans was quantified 
immunohistochemically with an antibody that recognized the "stub" left over after 
digestion with heparitinase 111. In the SHR and WKY animals the media, basement 
membrane, and endothelial layer stained heavily for heparan sulfate proteoglycan (Figure 
41). The intensity of staining in the endothelial and basement membrane layers was 
quantified and compared between animals, indicating an increase in endothelial heparan 
sulfate proteoglycan staining of 58% in comparing the SHR rats to WKY controls. A 
similar analysis was performed following immunohistochemical staining for heparanase 
and an increase in heparanase expression of hypertensive rats was found to be two fold 
increased versus control rats (Figure 42). Local medial thickness correlated strongly with 
local endothelial heparanase staining (Figure 43; R = 0.879, p < 0.0005). 
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WKY 
SHR 
SHR 
Figure 40. Hematoxylin and eosh staining of Wistar-Kyoto (WKY) and spontaneously 
hypertensive (SHR) rat aortae. 
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Figure 41. Immunohistochemical staining for heparan sulfate epitopes in Wistar-Kyoto (WKY) 
and spontaneously hypertensive (SHR) rat aortae. *statistically significant comparison (p < 
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Figure 42. Immunohistochemical staining for heparanase in Wistar-Kyoto (WKY) and 
spontaneously hypertensive (SHR) rat aortae. *statistically significant comparison ( p  < 0.05). 
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Medial Thickness (urn) 
Figure 43. Quantitative morphometry of vessel remodeling in SHR and WKY rats. Correlation 
between medial thickening and endothelial heparanase expression in SHR (m) and WKY (a) rats. 
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Hypertension Alters Transforming Growth Factor-Beta Expression 
and Phosphorylation State of Intracellular Signaling Intermediates 
In our studies hypertension causes a redistribution of TGF-p within the aorta. In 
the hypertensive animals the endothelial staining for TGF-p was increased and the medial 
staining reduced (Figure 44). A similar distribution of staining was found for 
phosphorylated Smad-2, a downstream element of TGF-p receptor signaling (Figure 45). 
Immunohistochemical staining also revealed an increase in endothelial staining for 
phosphorylated p38 MAPK and ERK (Figure 46 and Figure 47). The amount of total 
Spl was found to increase in the hypertensive animals as well (Figure 48). 
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Figure 45. Irnrnunohistochemical staining for phosphorylated Smad-2 in Wistar-Kyoto 
(WKY) and spontaneously hypertensive (SHR) rat aortae Cp < 0.05, n = 4). 
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SHR 
Figure 46. Immunohistochemical staining for phosphorylated p38 in Wistar-Kyoto (WKY) and 
spontaneously hypertensive (SHR) rat aortae Cp < 0.05, n = 4). 
Page 98 
WKY SHR 
Figure 47. Immunohistochemical staining for phosphorylated ERK in Wistar-Kyoto (WKY) 
and spontaneously hypertensive (SHR) rat aortae Cp < 0.05, n = 4). 
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SHR 
Figure 48. Immunohistochemical staining for transcription factor Spl in Wistar-Kyoto (WKY) 
and spontaneously hypertensive (SHR) rat aortae m . 0 5 ,  n = 4). No counterstain was used in 
this staining. 
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Correlation Analysis of Immunocytochemical Staining 
To establish relationships between the various signaling factors examined in this 
work we performed a correlation analysis. This analysis revealed strong correlations 
between medial thickness, p38, ERK, and TGF-p in the endothelium (shown in Table 2, 
Figure 49, and Figure 50). Correlations values (R) range from 0.7 to 0.9 with a p-value 
less than 0.05. A similar analysis was performed examining the medial staining but no 
significant correlations were found (Table 3). 
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Table 2. Correlation Analysis of Immunohistochemical Staining of the Endothelium 
Correlation Matrix (R) 
p-ERK p-p38 TGF-fl p-Smad2 Medial Thickness 
Phospho-ERK 1.000 0.817 0.740 0.790 0.729 
Phospho-p38 0.81 7 1 .OOO 0.793 0.967 0.890 
TG F-fl 0.740 0.793 1 .OOO 0.793 0.902 
Phospho-Smad2 -0.51 1 -0.846 -0.631 1 .OOO -0.694 
Medial Thickness 0.729 0.890 0.902 0.856 1 .OOO 
t Statistic 
p-ERK p-p38 TGF-fl p-Smad2 Medial Thickness 
p-ERK 3.471 2.692 2.882 2.61 0 
P 3.471 3.191 8.497 4.793 
TG F-fl 2.692 3.191 2.91 2 5.106 
p-Smad2 1.329 3.549 1.819 2.1 53 
Medial Thickness 2.61 0 4.793 5.106 3.707 
Correlation Significance (P) 
p-ERK p-p38 TGF-0 p-Smad2 Medial Thickness 
p-ERK 0.013 0.036 0.035 0.040 
~ - ~ 3 8  0.01 3 0.019 0.000 0.003 
TG F-fl 0.036 0.01 9 0.033 0.002 
p-Smad2 0.241 0.016 0.129 0.084 
Medial Thickness 0.040 0.003 0.002 0.014 
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Figure 50. Correlation scatterplots for statistically significant 
correlations on the immunohistochemical staining of the 
endothelium on Wistar-Kyoto and spontaneously 
hypertensive rats. 
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Table 3. Correlation Analysis of Immunohistochemical Staining of the arterial media. 
- - 
Correlation Matrix (R) 
p-ERK p-p38 TGF-p p-Smad2 Medial Thickness 
p-ERK 1 .OOO -0.016 -0.084 0.790 -0.480 
P-P~B -0.016 1 .OOO 0.214 0.967 -0.141 
TGF-8 -0.084 0.214 1 .OOO 0.793 -0.095 
p-Smad2 0.482 0.677 0.519 1 .OOO -0.694 
Medial Thickness -0.480 -0.141 -0.095 0.856 1 .OOO 
t Statistic 
p-ERK p-p38 TGF-p p-Smad2 Medial Thickness 
p-ERK 0.040 0.207 1.229 1.342 
~ - ~ 3 8  0.040 0.538 2.057 0.349 
TGF-p 0.207 0.538 1.359 0.235 
p-Smad2 1.229 2.057 1.359 2.1 53 
Medial Thickness 1.342 0.349 0.235 2.1 53 
Correlation Significance 
iP\ 
p-ERK p-p38 TGF-p p-Smad2 Medial Thickness 
p-ERK 0.969 0.843 0.274 0.228 
P-P~B 0.969 0.610 0.095 0.739 
TG F-p 0.843 0.610 0.232 0.822 
p-Smad2 0.274 0.095 0.232 0.084 
Medial 
Thickness 0.228 0.739 0.822 0.084 
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Discussion 
The animal model of hypertension demonstrated an increase in heparanase and 
heparan sulfate proteoglycans in the endothelium of hypertensive rats. These results 
support that similar processes that control the in-vitro response to mechanical load may 
be governing the vascular response to hypertension. Both heparanase and heparan sulfate 
proteoglycans were increased in our in-vitro studies examining mechanical stretch on the 
endothelium. 
TGF-p has been shown to be important in regulating the pathobiology of many 
vascular disorders [153]. Its role is made complex by its ability to act as both a 
stimulator and inhibitor of growth depending on other factors [137, 1381. Our results 
show increases in active TGF-B in the endothelium and a decrease in TGF-p in the 
media. Our previous in-vitro studies in Chapter 3 suggest that this may be due to the 
mechanically-induced activation of TGF-p by endothelial cells. These results support our 
paradigm of load increasing endothelial inhibition as well as increasing vascular smooth 
muscle cell proliferation. An interesting question not addressed in the current work is the 
reason for the loss of TGF-p in the media of the artery. Since the endothelial cell is 
producing a greater amount of TGF-p, it implies that the vascular smooth muscle cells 
are actively degrading or removing TGF-p. 
The strong correlations between TGF-B and p381ERK support the occurrence of 
an autocrine signaling loop in the endothelium of the SHR rats. Spontaneously 
hypertensive rats are known to have medial hypertrophy in the aorta due to their 
hypertension that correlates with the local severity of the blood pressure increase [154]. 
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The fact that the members of the TGF-p autocrine signaling loop correlates with the 
thickness of the vascular wall implies a relationship between this signaling and the in- 
vivo mechanical environment. 
One fundamental question that remains from this work is the role of heparanase in 
controlling the vascular remodeling in response to hypertension. The strong correlation 
between the thickness of the aorta and the heparanase expression in the overlying 
endothelium indicates that the balance between heparanase and heparan sulfate 
proteoglycan plays a role in growth factor induced hyperplasia as well as proliferation. 
However, it is unclear whether heparanase expression serves as a means to increases the 
inhibition of the endothelial cell or as a pathophysiologic mechanism underlying the 
endothelial dysfunction in hypertension. 
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Conclusion 
These results are consistent with our model of vascular remodeling to mechanical 
strain. The endothelium in hypertension showed increases in HSPG, TGF-p and 
intracellular signaling factors that matched well with the in-vitro results presented in 
Chapter 3. It is interesting to note that alterations occurred in the media as well as in the 
endothelium. This supports the notion that the vascular smooth muscle cells may be 
counteracting the increased inhibition of the endothelium by inactivating or degrading 
TGF-p. In this chapter we identified a close correlation between endothelial heparanase 
expression and vascular wall thickness. These results imply that heparanase may play an 
essential role in controlling vascular remodeling. We will explore the fundamental 
question of heparanase's role in vascular remodeling in more detail in the following 
chapter. 
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Chapter 5: Role of Heparanase in Vascular Remodeling 
Introduction 
Heparanase is an enzyme that degrades heparan sulfate infrequently to yield 
glycosaminoglycan chains that are 10-20 disaccharides in length. The aim of this section 
is to examine the role of heparanase expression in endothelial cells in the macrovascular 
system and in injury. The fundamental question is whether heparanase serves as an 
enhancer or inhibitor of vascular smooth muscle cell proliferation. To study this 
question, heparanase expression in endothelial cells was enhanced or inhibited using 
overexpression and siRNA vectors. To examine the role of heparanase in vascular 
remodeling we used an in-vivo model diabetes and vascular injury. 
Materials and Methods 
Cell Culture. Rat vascular smooth muscle cells (RVSMCs) were isolated from fresh or 
rat aortae. These cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, 
Gibco BRL Life Technologies, Gaithersburg, MD) supplemented with 5% calf serum 
(Hyclone, Logan UT) and 100 units per ml of penicillin, 100 pg per ml streptomycin 
sulfate, and 2 rnM L-glutamine. Human umbilical vascular endothelial cells (HUVECs; 
Cambrex, Walkersville, MD) were grown in DMEM with 5% fetal bovine serum 
(Hyclone) and EGM-2 supplements (Cambrex). All smooth muscle cells were used at 
passages 4 to 5 and all endothelial cultures were used at passage 3 to 5. All cells were 
incubated at 37Â° in a humidified atmosphere containing 5% C02. 
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Gene Silencing and Expression Vectorsm Gene silencing for heparanase was performed 
using previously validated hairpin RNA sequence[ll6]. Briefly, oligonucleotides with 
the sequence 5'- 
GATCCCCACTCCAGGTGGMTGGCCCTTCMGAGAGGGCCATTCC 
ACCTGGAGTTTTTTGGM-3' and 5'-GATCCCCACTCCAGGTGGMTGGCCCTT 
CMGAGAGGGCCATTCCACCTGGAGTTTTTTGGM-3' were hybridized and 
cloned into a pSUPER expression vector (OligoEngine, Inc., Seattle, WA). Confirmation 
of insertion of the siRNA sequence was performed using automated DNA sequencing by 
the Biopolymers Laboratory at the MIT Center for Cancer Research, Cambridge, MA. 
The h l l  length cDNA for human heparanase in a pCMV6 vector was obtained fiom 
Origene Technologies Inc. (Rockville, MD). 
Transfection of HUVEXsm Transfection of HUVECs was performed using Targefect F- 
2, according to the manufacturer's protocol (Targeting Systems, Santee, CA). 
Transfection conditions were optimized using a pTRACER vector (Invitrogen) that 
constitutively expresses green fluorescent protein. 
Animal Model of Vascular Injury. Zucker fatty (Crl:(ZUC)-$aBR) and Zucker lean rats 
were used in an animal model of vascular injury and stenting in the presence of metabolic 
syndrome and insulin resistance[l55]. At the time of stenting the rats were 12 and 14 
weeks old for the fatty and lean rats, respectively. The rats were anesthetized using 
isofluorane, given a 100 Ukg dose of heparin, and a small incision was made to expose 
the right femoral artery. This artery was ligated and an arteriotomy was performed 
proximal to the ligature. A 0.014'' angioplasty guidewire was passed into the aorta and an 
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9-mm long endovascular stent (Nirflex; Medinol Inc., Tel Aviv, Israel) mounted on a 15 
x 2.5-mm angioplasty balloon (Crossail; Guidant Inc.? Santa Clara? CA) was passed into 
the abdominal aorta (Figure 5 1). The stent was deployed with a 15 s inflammation at 8 
atm inflation pressure. Post-stenting the animals were given aspirin via drinking water at 
an approximate dose of 5 mg/kg/day. The animals were sacrificed at 14 days post- 
stenting using inhaled C02. 
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Figure 51. Photographs of the stating procedure. A) The femoral arteriotomy prior to 
catheter insertion and stent placement. B) The stent in the abdominal aorta at time of 
harvest. 
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Smooth Muscle Cell Proliferation Assay* Rat smooth muscle cells were passaged into 
six-well plates at low density. Endothelial cell conditioned media was colected and used 
in an assay of vascular smooth muscle cell proliferation. Smooth muscle cells were serum 
starved in 0.5% calf serum for 24 hours, washed with PBS, and incubated in conditioned 
media with 1 pCiIm1 3~-thymidine for 24 hours. The cells were then washed three times 
with PBS at 4OC. The cells were then incubated with 10% TCA for 30 min at 4OC, washed 
twice in 95% ethanol, and solubilized in 1 ml of 0.25 M NaOH with 0.1% SDS for 1 
hour. The samples were then added to scintillation cocktail and radioactivity measured 
using a liquid scintillation counter. 
Statistics* All results are shown as mean standard deviation. An ANOVA was used to 
make comparisons between groups of continuous variables. A two-tailed Student's t test 
was used to make comparisons between groups; p < 0.05 was defined as being 
statistically significant. The Pearson product moment correlation statistic was used as a 
measure of correlation between variables. 
Results 
To investigate the role of heparanase expression by endothelial cells, we over- 
and underexpressed heparanase using a vector expressing heparanase and a vector 
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expressing a small interfering RNA (siRNA) hairpin sequence specific to heparanase. 
Human umbilical vein endothelial cells were transfected with the gene silencing vector 
(siHPA) containing an insert to express an siRNA sequence specific for inhibiting 
heparanase, a vector expressing the heparanase protein (pHPA), or a control vector for 
expressing siRNA but with no siRNA sequence (siCON). Following transfection, the 
cells were fixed, stained, and examined by immunofluorescent microscopy to confirm 
alterations in the expression of heparanase protein (Figure 52). Transfected cells were 
also lysed and assayed for heparanase by immunoblotting to confirm alterations in 
protein expression of heparanase (Figure 53). Transfection of cells with siRNA specific 
to heparanase led to almost complete silencing of heparanase protein expression. 
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Figure 52. Immunocytochemical staining for heparanase in endothelial cells transfected with a 
control vector (&ON), a heparanase targeted siRNA vector (siHPA) or a heparanase expression 
vector (pHPA). Cells were transfected with the various vector, incubated for 48 hrs and then 
stained using antibody to heparanase and a fluorescently labeled secondary antibody. 
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Figure 53. Western blot for heparanase in endothelial cells transfected with a control vector 
(siCON), a heparanase targeted siRNA vector (siHPA) or a heparanase expression vector 
(pHPA). Cells were transfected with the various vector, incubated for 48 hrs, lysed and 
subjected to Western blot analysis. 
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One of the primary functions of the macrovascular endothelial cell layer is to 
control vascular smooth muscle cell (vSMC) growth and proliferation. Secreted heparan 
sulfate proteoglycans (HSPGs) are the major inhibitory molecules involved in endothelial 
control of vSMC proliferation [6,68]. To examine heparanase's role in modulating this 
control, conditioned media was prepared from each transfection group and applied in an 
assay of SMC proliferation (Figure 54). Overexpression of heparanase removed most of 
the inhibitory properties of endothelial cell conditioned medium (90.8 Â 8.8% thymidine 
incorporation versus control, p = not significant). Interestingly, the siRNA knock-down 
of heparanase resulted in highly inhibitory conditioned medium, leading to almost 
complete inhibition of SMC growth in the proliferation assay (3.3 1.5% thymidine 
incorporation versus control, p < 0.05). These data indicate that endothelial expression of 
heparanase can serve as an effective mechanism to control endothelial inhibition of SMC 
proliferation. 
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Media 
Figure 54. Vascular smooth muscle cell proliferation when exposed to endothelial cell 
conditioned medium from cells transfected with a control vector ( S O N ) ,  a heparanase targeted 
siRNA vector (siHPA) or a heparanase expression vector (pHPA). 
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To further examine the mechanism of heparanase control of vSMC inhibition, 
endothelial cells were metabolically labeled with tritiated glucosamine and the 
conditioned media analyzed using ion exchange and size exclusion chromatography for 
glycosaminoglycan (GAG) expression (Figure 55 through Figure 58). Overexpression of 
heparanase led to a marked reduction in endothelial cell surface associated GAG and 
HSPG (Figure 58). Conversely, a reduction in heparanase produced an increase in cell 
surface GAG accumulation (Figure 58). The media GAG appeared to be less affected by 
heparanase expression, only showing a small decrease in total proteoglycan and HSPGs 
for heparanase overexpressing cells. 
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Fraction Number 
Figure 55. Total proteoglycans in endothelial cell conditioned media separated by ion exchange 
chromatography. Cells transfected with a control vector (black line), a heparanase targeted 
siRNA vector (blue line) or a heparanase expression vector (red line). The applied salt gradient 
(dotted line) on the second axis. 
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Fraction Number 
Figure 56. Heparan sulfate proteoglycans in endothelial cell conditioned media separated by ion 
exchange chromatography. Cells transfected with a control vector (black line), a heparanase 
targeted siRNA vector (blue line) or a heparanase expression vector (red line). The applied salt 
gradient (dotted line) on the second axis. 
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Figure 57. Total proteoglycans on the endothelial cell surface separated by ion exchange 
chromatography. Cells transfected with a control vector (black line), a heparanase targeted 
siRNA vector (blue line) or a heparanase expression vector (red line). The applied salt gradient 
(dotted line) on the second axis. 
Page 122 
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Figure 58. Heparan sulfate proteoglycans on the endothelial cell surface separated by ion 
exchange chromatography. Cells transfected with a control vector (black line), a heparanase 
targeted siRNA vector (blue line) or a heparanase expression vector (red line). The applied salt 
gradient (dotted line) on the second axis. 
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In addition to hypertension, percutaneous vascular intervention is another 
common mechanical stimulus for arterial remodeling. The affects of overexpression of 
heparanase on endothelial control of vSMC proliferation suggest that heparanase may 
also play a major role in modulating vascular response to injury. Platelets and 
inflammatory cells are known to express heparanase, providing a source of heparanase 
independent of the endothelium. We recently showed that vascular injury was 
exacerbated by the diabetic state in the Zucker rat model of type I1 diabetes[155]. To 
examine the role of heparanase in vascular injury we placed stents in the aortae of lean 
and fatty Zucker rats. Two weeks after stenting the animals were sacrificed and plastic 
embedded sections were prepared from the stented regions of the aortae. 
Hematoxylin and eosin and van Geissen staining of aortae showed an increase in 
neointimal thickness comparing the fatty to lean Zucker rats (Figure 59 and Figure 60). 
Imrnunohistochemical staining for the expression of heparanase in the neointima of fatty 
rats showed intense staining for heparanase in the neointimal region surrounding the stent 
strut (Figure 61). A strong correlation was found between the legion neointimal thickness 
and heparanase expression (R = 0.749, p < 0.0005, Figure 62). 
Page 124 
LEAN - - FATTY 
Figure 59. Hematoxylin and eosin staining of histological sections of the stented abdominal 
aorta. 
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Figure 60. Elastic fiber (Verhoff Van Geisen) staining of histological sections of the stented 
abdominal aorta. 
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Figure 61. Irnrnunohistochemical staining for heparanase of histological sections of the stented 
abdominal aorta. 
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Neointimal Thickness (urn) 
Figure 62. Correlation analysis comparing lesion thickness with heparanase staining. 
Correlation between medial thickening and endothelial heparanase expression in SHR (H) and 
WKY (0)  rats. 
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Discussion 
This study identifies endothelial heparanase as a regulator of vascular remodeling 
and provides evidence that altered heparanase expression may underlie the 
pathophysiology of common vascular disorders. Previous work on heparanase has 
focused primarily on its role in modulating tumor cell invasion and angiogenesis. 
Despite the discovery of heparanase expression in endothelial cells two decades ago, the 
functional role of this expression in arterial biology had not been explored. Our study 
shows that heparanase expression serves to counterbalance the expression of growth 
inhibitory heparan sulfate proteoglycans in endothelial cells, providing a feedback 
mechanism for endothelial cells to have fine control of vascular smooth muscle cell 
growth and proliferation. 
Our studies show that gene silencing and enhancement of heparanase expression 
in endothelial cells leads to dramatic modulation of the conditioned media inhibitory 
properties towards vascular smooth muscle cell. Surprisingly, the silencing of 
heparanase expression resulted in almost complete inhibition of vascular smooth muscle 
cell growth. One potential mechanism of action of heparanase is to cleave extracellular 
matrix HSPG causing a release of matrix bound growth factors (particularly FGF-2). 
Heparanase isolated from platelets has been shown by others to release FGF-2 increasing 
the proliferation of vSMC [119]. While this mechanism may play a role in increasing 
proliferation in endo thelial overexpression of heparanase, it is unlikely to explain the 
large increase in inhibition of vSMC growth observed in the heparanase silenced cells. It 
is also notable that the medium used for these experiments contained considerable 
amounts of FGF-2 in serum and as a supplement. Similar inhibition results were 
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obtained using the isolated proteoglycans as with full conditioned media, indicating that 
release of FGF-2 was not a major mechanism acting in this system. Heparanase appeared 
to act on endothelial cells by causing the cleavage of cell surface heparan sulfate 
proteoglycans. This result is consistent with prior work that found that heparanase did not 
cut heparan sulfate proteoglycans in conditioned media [I561 and also that macrophage 
lysosomal lysates can digest cell surface heparan sulfate proteoglycan of smooth muscle 
cells [ 1 5 71. 
Previous work has shown that heparanase does not completely digest heparan 
sulfate into disaccharides but rather it cuts infrequently to yield chains of 10-20 sugar 
units [ 1581. Studies examining the specific structural determinants of heparin's 
inhibitory properties have shown that a minimum length of a hexasaccharide was needed 
to get inhibitory properties but also revealed a dependence on sulfation [159]. A major 
question that arises is whether these short polysaccharides are more or less inhibitory 
than the original, longer heparan sulfate chain. Our work indicates that heparanase acts 
on cell surface heparan sulfate proteoglycan cutting them to make small fragments that 
increase vSMC proliferation. Cell surface heparan sulfate proteoglycans can serve as 
coreceptor facilitating FGF receptor signaling [82] thus these heparan sulfate 
proteoglycans, in particular, would be particularly effective in increasing vSMC 
proliferation when released from cells by heparanase. The released cell surface heparan 
sulfate proteoglycans serve to counterbalance the inhibitory properties of the secreted and 
matrix HSPG that endothelial cells produce. 
In-vivo, an animal model of hypertension demonstrated an increase in heparanase, 
HPSG, and Spl in the endothelium of hypertensive rats. These results support that similar 
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processes that control the in-vitro response to mechanical load may be governing the 
vascular response to hypertension. Spontaneously hypertensive rats are known to have 
medial hypertrophy in the aorta due to their hypertension[154]. The strong correlation 
between the thickness of the aorta and the heparanase expression in the overlying 
endothelium illustrates that the balance between heparanase and HSPG plays a role in 
growth factor induced h yperplasia as well as proliferation. 
Prior work has shown increased heparanase expression in the endothelium of 
apoE-null mice and in endothelial cells exposed to fatty acids [160]. We examined the 
effect of the mechanical injury of endovascular stenting on rats in the context of the 
Zucker rat model. Our studies revealed a strong correlation between neointimal 
heparanase expression and neointimal thickness. This work indicates that the increased 
fatty acids act in inflammatory cells in vascular injury, causing increased expression of 
heparanase and increased neointimal formation. A secondary mechanism may be the 
enhanced of heparanase expression in invading inflammatory cells. Heparin and PI-88 (a 
synthetic heparin analogue) have been used in animal models to reduce neointimal 
formation [16 1, 1621. Both of these compounds can inhibit heparanase activity but also 
have many other activities including growth factor binding and direct activity on vascular 
smooth muscle cell. 
Taken together, our results define a new role for heparanase as a regulator of 
vascular remodeling. In this model heparanase serves as a control point allowing 
endothelial cells to modulate between inhibition and stimulation of vascular smooth 
muscle cells by utilizing one molecule. Further, these findings may have important 
implications in vascular disease progression. Aberrant heparanase may serve as a 
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common pathophysiological mechanism governing vascular remodeling under different 
pathological disease states. While specific small molecule inhibitors have long been 
sought after for the treatment of metastatic cancers, these results indicate that these 
molecules may also have a role in the treatment of postangioplasty restenosis, 
atherosclerosis, and hypertension. 
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Conclusions 
In this chapter we have given evidence that endothelial heparanase expression 
causes decreased vascular smooth muscle cell inhibition. Further we have shown a 
strong correlation between the heparanase expression and neointimal thickness in an 
animal model of injury and diabetes. This work identifies heparanase as a major 
regulator of vascular remodeling. Heparanase inhibition is currently a major thrust of 
commercial research for cancer therapy. Our results imply that these therapeutics may be 
useful in controlling aberrant vascular remodeling as well. 
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Chapter 6: Conclusions and Future Directions 
This thesis presents a body of work examining the fundamental biological 
mechanisms that govern vascular remodeling. In Chapter 3, we examined how 
endothelial cells change their control of vascular smooth muscle cells in response to 
mechanical environment. These changes were shown to be mediated, in part, by heparan 
sulfate proteoglycan. The changes in heparan sulfate proteoglycans were controlled by 
intracellular signaling pathways of MAPK and p3 8 MAPK, along with a TGF- p 
autocrine signaling. In Chapter 4, we found that the endothelium in hypertensive animals 
appeared to be similarly regulated by the increased mechanical strains. The hypertensive 
animals had increased endothelial heparanase expression that correlated with medial 
thickening. Finally, we examined the role of heparanase in modulating endothelial 
control over vascular smooth muscle cell proliferation and found that increasing 
endothelial heparanase expression caused a decreased vascular smooth muscle cell 
inhibition. 
Future studies should be done to further examine the mechanotransduction 
pathway that was partially elucidated in this work. In particular it will be essential to 
identify the molecules responsible for the activation of TGF-p in response to load. A 
particularly appealing candidate group is the matrix metalloproteases (MMPs) some of 
which can activate TGF-p and have been modulated with other types of mechanical strain 
[ 1631. Another fascinating possibility is that the endothelial cell is activating the TGF-p 
through direct integrin-mediated pathway. Thrombospondin is known to bind to TGF-p 
and it has been proposed that certain integrins may be involved in activating TGF-p in 
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this state [54]. One potential theory is that the integrins could bind to TGF immobilized 
thrombospondin and mechanical force could serve as the activating factor. 
A major portion of future work will focus on modulating the expression of 
heparanase to get in-vivo overexpression and underexpression. We recently created a 
lentiviral vector capable of in-vivo knockdown of heparanase. This tool can be used in 
several ways. The first is to give local delivery to arteries prior to vascular injury. In 
preliminary tests we delivered a GFP expressing virus in a rat model of carotid balloon 
injury. However, immunostaining for GFP showed that the virus did not penetrate the 
into the media of the artery.. Another approach is to use the virus to create transgenic 
animals. In this way we could study the affects of heparanase knockdown in 
hypertensive and diabetic Zucker rats. This method would likely be more effective than 
local delivery but requires a significant time investment. Another possibility that is being 
explored is to use small molecule inhibitors to heparanase as a means to knockdown 
heparanase activity. We recently started a collaboration with a research group that will 
provide us with a small molecule inhibitor towards heparanase. This methodology has 
great potent for clinical application. Drug eluting stents have been shown to work less 
effectively on diabetic patients. Combination therapy with a heparanase inhibitor and a 
currently used drug might create a stent specifically for use in these at risk patients. 
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